NOS2 and opsoclonus-myoclonus syndrome: We further demonstrated that OMS treatment increased the expression of M1-related proinflammatory cytokines, inducible nitric oxide synthase (iNOS), and mitochondrial reactive oxygen species (mtROS) in BMDMs.